Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98

作者：

Siebenhaar, Frank ^{[1
]}

Redegeld, Frank A. ^{[2
]}

Bischoff, Stephan C. ^{[3
]}

Gibbs, Bernhard F. ^{[4
,5
]}

Maurer, Marcus ^{[1
]}

机构：

[1] Charite, Dept Dermatol & Allergy, Berlin, Germany

[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands

[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany

[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England

[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany

来源：

TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期

关键词：

RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;

D O I：

10.1016/j.it.2017.10.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.

引用

页码：151 / 162

页数：12

共 50 条

[21] Mast Cells in Cardiovascular Disease: From Bench to Bedside
Hermans, M. A. W.
van Lennep, J. E. Roeters
van Daele, P. L. A.
Bot, I.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (14)
[22] Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets
Yang, Liuna
Mao, Kanming
Yu, Honglin
Chen, Jialong
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2020, 15 (04) : 830 - 837
[23] Targeting Mast Cells with Biologics
Lyons, Jonathan J.
Metcalfe, Dean D.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2020, 40 (04) : 667 - 685
[24] Quantification of mast cells in different stages of periodontal disease
Marjanovic, Dragan
Andjelkovic, Zlatibor
Brkic, Zlata
Videnovic, Goran
Sehalic, Meliha
Matvjenko, Vladimir
Lestarevic, Snezana
Djordjevic, Nadica
VOJNOSANITETSKI PREGLED, 2016, 73 (05) : 458 - 462
[25] Mast cell proteases as pharmacological targets
Caughey, George H.
EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 778 : 44 - 55
[26] Botulinum toxin blocks mast cells and prevents rosacea like inflammation
Choi, Jae Eun
Werbel, Tyler
Wang, Zhenping
Wu, Chia Chi
Yaksh, Tony L.
Di Nardo, Anna
JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 93 (01) : 58 - 64
[27] Cellular and Molecular Mechanisms of Mast Cells in Atherosclerotic Plaque Progression and Destabilization
Elieh-Ali-Komi, Daniel
Bot, Ilze
Rodriguez-Gonzalez, Monica
Maurer, Marcus
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2024, 66 (01) : 30 - 49
[28] Challenges in validating candidate therapeutic targets in cancer
Settleman, Jeffrey
Sawyers, Charles L.
Hunter, Tony
ELIFE, 2018, 7
[29] Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics
Gordillo-Maranon, Maria
Zwierzyna, Magdalena
Charoen, Pimphen
Drenos, Fotios
Chopade, Sandesh
Shah, Tina
Engmann, Jorgen
Chaturvedi, Nishi
Papacosta, Olia
Wannamethee, Goya
Wong, Andrew
Sofat, Reecha
Kivimaki, Mika
Price, Jackie F.
Hughes, Alun D.
Gaunt, Tom R.
Lawlor, Deborah A.
Gaulton, Anna
Hingorani, Aroon D.
Schmidt, Amand F.
Finan, Chris
NATURE COMMUNICATIONS, 2021, 12 (01)
[30] Preclinical therapeutic targets in diffuse midline glioma
Meel, Michael Hananja
Kaspers, Gertjan J. L.
Hulleman, Esther
DRUG RESISTANCE UPDATES, 2019, 44 : 15 - 25

← 1 2 3 4 5 →